$arna expecting -140.19% YoY EPS growth, -94.81% YoY revenue growth, weak PAH data, UC drug has admitted patent issues, pipe years from FDA, only drug has 2 patent challenges. Yes. Worthy of upgrade. #stocks#biotech#pharma
$ARNA, expected to deliver highly negative earnings growth in the next few years, which doesn’t help build up its investment thesis. Risk of future uncertainty is high. #stocks#pharma $qqq $spy $dia $iwm $ibb $xbi $vrtx $gild $pfe $mrk $juno $blue $exas $celg #biotechnology
$arna China deal breaks down to $1.2 M in upfront money and a max of $21.2 M in milestones and development per drug then tiny royalty, same for the other included big territories. Will hurt any potential U.S and E.U deal. #stocks
Just when I think my capacity to be surprised has been exhausted, Pres Trump declares that he accepts Putin's word (over CIA's) that he never interfered in our election & worries the Russian leader feels insulted by charge to contrary